Novartis AG (NYSE:NVS)

87.07
Delayed Data
As of Sep 20
 +0.72 / +0.83%
Today’s Change
73.17
Today|||52-Week Range
95.00
+13.28%
Year-to-Date
Pharma Stock Roundup: FDA Approves Expanded Use of MRK/J&J's Drugs & Other Updates
Sep 20 / Zacks.com - Paid Partner Content
Has Novartis (NVS) Outpaced Other Medical Stocks This Year?
Sep 12 / Zacks.com - Paid Partner Content
Biogen's New Study to Test Higher Dose of SMA Drug Spinraza
Sep 19 / Zacks.com - Paid Partner Content
4 Big Drugmakers Boasting Impressive Oncology Pipelines
Sep 11 / Zacks.com - Paid Partner Content
Novartis Announces New Data on Spondylitis Drug Cosentyx
Sep 17 / Zacks.com - Paid Partner Content
Allergan's Filings for Abicipar Pegol Accepted in U.S/Europe
Sep 11 / Zacks.com - Paid Partner Content
J&J Files sBLA for Tremfya With FDA for Psoriatic Arthritis
Sep 17 / Zacks.com - Paid Partner Content
Novartis Announces Positive Long-Term Data on Migraine Drug
Sep 09 / Zacks.com - Paid Partner Content
Alder (ALDR) Stock Up on Acquisition Agreement With Lundbeck
Sep 17 / Zacks.com - Paid Partner Content
Pfizer is a Top Drugmaker: Is it the Right Time to Buy It?
Sep 06 / Zacks.com - Paid Partner Content
Is Novartis (NVS) a Great Value Stock Right Now?
Sep 17 / Zacks.com - Paid Partner Content
FDA Grants Priority Review to Global Blood's SCD Candidate
Sep 06 / Zacks.com - Paid Partner Content
Biogen Stops Late-Stage Studies on Alzheimer's Candidate
Sep 16 / Zacks.com - Paid Partner Content
Novartis' Capmatinib Gets Breakthrough Therapy Tag From FDA
Sep 06 / Zacks.com - Paid Partner Content
Breast Cancer Drugs May Inflame Lungs Per FDA Safety Alert
Sep 16 / Zacks.com - Paid Partner Content
Pharma Stock Roundup: AGN's Opioid Settlement, Line Extension Nod in EU for MRK, JNJ Drugs
Sep 06 / Zacks.com - Paid Partner Content
Adverum Reports Data From Phase I Wet AMD Study, Stock Down
Sep 13 / Zacks.com - Paid Partner Content
4 Biotech Stocks With Big Catalysts in September
Sep 05 / MotleyFool.com - Paid Partner Content
Puma Biotech's sNDA for Nerlynx Combo Gets FDA Acceptance
Sep 12 / Zacks.com - Paid Partner Content
AstraZeneca's Tagrisso Gets Nod in China for First-Line NSCLC
Sep 05 / Zacks.com - Paid Partner Content
J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients
Sep 12 / Zacks.com - Paid Partner Content